Cetuximab is a chimeric monoclonal antibody, one of the first anti-EGFR antibodies to be developed, and has been approved for the treatment of colorectal and head and neck squamous cell carcinoma [29]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.